Patients

MOMENTUM Clinical Trial

MOMENTUM (NCT04173494) is a randomized, double-blind Phase 3 clinical trial of momelotinib versus danazol (n=180; 2:1) in symptomatic, anemic patients previously treated with an approved JAK inhibitor. The study is designed to confirm [in a statistically compelling manner] the unique benefits of momelotinib on all three hallmarks of myelofibrosis (MF): symptoms, anemia and splenomegaly.

The primary endpoint of the study is the MFSAF Total Symptom Score (TSS) response rate at Week 24. Secondary endpoints include confirmatory measures of anemia benefit and splenic response rate.

Danazol has been selected as an appropriate treatment comparator given its use to ameliorate anemia in myelofibrosis patients, as recommended by NCCN and ESMO guidelines. Patients will be randomized 2:1 to receive either momelotinib or danazol. After 24 weeks of treatment, patients on danazol will be allowed to crossover to receive momelotinib. Early cross-over to momelotinib is available for confirmed symptomatic splenic progression.

The study’s co-Chief Investigators are Dr. Srdan Verstovsek, Chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas and Dr. Ruben Mesa, Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. Both Dr. Verstovsek and Dr. Mesa are world-renowned clinician scientists in the myeloproliferative neoplasm field. Dr. Verstovsek and Dr. Mesa have been involved in the development of most of the investigational and approved agents for the treatment of myelofibrosis. In particular, Dr. Verstovsek and Dr. Mesa have been involved in the development of momelotinib since 2011, both as advisors and as clinical investigators.

For more information, please visit momentumtrial.com or contact info@momentumtrial.com.

Access to Investigational Therapies

Sierra Oncology is focused on executing a successful clinical trial program for momelotinib in patients with myelofibrosis. For information on clinical trial participation and status updates, please visit www.clinicaltrials.gov. Sierra Oncology does not currently provide expanded access (also known as “Compassionate Use”, “Named Patient” or “Special Access” use) to our investigational therapies.

At the present time, Sierra Oncology does not plant o provide expanded access of momelotinib or any of our other investigational medicines. If you have questions about Expanded Access or Compassionate Use, please speak with your healthcare provider or contact info@sierraoncology.com. We will respond to any inquires as soon as possible.

Resources for Patients and Care Partners